Price
No data yet.
Social Signal Score
Revenue
$8.86M-1.33%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Yujiro S. Hata
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 145
- Beta
- -0.09
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 18.15
Financials
Revenue
$8.86M-1.3%Net Income
$-112.45MEBITDA
$-121.17MFree Cash Flow
$-165.21MEPS (diluted)
$-1.22Shares Outstanding (diluted)
92.06M+143.7%Operating Expenses
$131.15MCash & Debt
$828.96MRevenue by Segment (annual)
$161.85MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $218.71M | $-113.70M | $-1.28 |
| 2024 | $7.00M | $-274.48M | $-3.36 |
| 2023 | $23.39M | $-112.96M | $-1.96 |
| 2022 | $50.93M | $-58.66M | $-1.42 |
| 2021 | $27.94M | $-49.76M | $-1.41 |
| 2020 | $19.54M | $-34.49M | $-1.31 |
| 2019 | $0.00 | $-41.98M | $-1.90 |
| 2018 | $0.00 | $-34.35M | $-2.41 |
| 2017 | $0.00 | $-11.86M | $-0.83 |
Valuation
IDYAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newsprnewswire.com·6h ago·Neutral
… clinical trial, and there will be joint governance to oversee the study SOUTH SAN FRANCISCO, Calif., Aug. 19, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it has entered into a clinical collaboration with Genentech, a member of the Roche Group, to evaluate the efficacy and safety of IDE892, its investigational, potential best-in-class MTA-cooperative PRMT5 inhibi…
View source ↗
Earnings
Tue, Nov 3(in 3 months)
Consensus estimate $-1.28 per share
Typical surprise -3.7% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$-1.22 vs $-1.06miss
- Tue, May 5$-1.11 vs $-1.07miss
- Tue, Feb 17$-0.94 vs $-0.95beat
- Tue, Nov 4$1.33 vs $-0.95beat
- Tue, Aug 5$-0.88 vs $-0.85miss
- Tue, May 6$-0.82 vs $-0.75miss
Estimates and results for IDYA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IDYA officers and directors.
- Bought
- $1.6m
- Sold
- $19.6m
1 trade
21 trades
- Ruiz Briseno Andressold
- Stein Jeffreybought
- White Michael Anthonysold
- White Michael Anthonysold
- Hata Yujiro Ssold
- Hata Yujiro Ssold
- Hata Yujiro Ssold
- Hata Yujiro Ssold
78 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.